Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.96 USD | -2.58% | -16.14% | +79.08% |
05-14 | Stephens Starts Inovio Pharmaceuticals With Overweight Rating, $20 Price Target | MT |
05-13 | Transcript : Inovio Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 13, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+79.08% | 291M | |
+64.92% | 62.59B | |
-1.85% | 41.18B | |
+44.76% | 40.29B | |
-8.93% | 27.9B | |
+13.05% | 26.21B | |
-21.96% | 19.09B | |
+4.21% | 13.08B | |
+25.74% | 12.26B | |
+27.42% | 12.05B |
- Stock Market
- Equities
- INO Stock
- News Inovio Pharmaceuticals, Inc.
- Inovio Pharmaceuticals : Receives Chinese Approval for Heterologous Prime-Boost Clinical Trials of COVID-19 DNA Vaccine Candidate